i2O Therapeutics is a drug delivery company developing safe and effective oral formulations of therapies traditionally limited to injections.
i2o is focused on creating the next generation of oral peptide and protein-based therapies.
i2O Therapeutics was founded in 2019 by Samir Mitragotri, Ravi Srinivasan, Kelly Ibsen, and Tyler Brown. The company is headquartered in Boston, Massachusetts.
i2O Therapeutics uses an innovative ionic liquid technology, this platform leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally.
i2O Therapeutics has raised $4M in a Seed round on April 09, 2020. The investment was led by Sanofi Ventures and JDRF T1D Fund.